Stockscreener 앱 받기
3.36
6.93%
-0.25
시간 외 거래:
3.34
-0.02
-0.60%
Soligenix Inc 주식(SNGX)의 최신 뉴스
Are Bears Losing Grip on Soligenix Inc.2025 Top Gainers & Fast Entry Momentum Trade Alerts - newsyoung.net
NovaBay Names New CEO, Rocket Soars As FDA Lifts Clinical Hold, Celldex Plunges, Soligenix On Watch - RTTNews
Companies Like Soligenix (NASDAQ:SNGX) Could Be Quite Risky - Yahoo Finance
SNGX: Dusquetide (SGX945) Granted Orphan Drug Designation for Behcet’s Disease - Yahoo Finance
Soligenix shares rise 9.46% premarket after receiving Nasdaq notice for non-compliance with equity requirement. - AInvest
Top Penny Stocks to Watch Now: Soligenix, Catheter Precision, and Wellgistics Health - AInvest
Promising Defense Stocks To Add to Your WatchlistAugust 18th - MarketBeat
Soligenix Plunges 27%—What's Behind the Sudden Sell-Off Amid Orphan Drug Designation? - AInvest
Soligenix (NASDAQ: SNGX) Awarded FDA Orphan Drug Designation for Dusquetide in Behçet’s Disease - The Globe and Mail
Why SNGX Gains 8% Amid Positive Trends? - StocksToTrade
Soligenix Plunges 17.74% After FDA Orphan Drug Designation - AInvest
Soligenix shares fall 18.55% premarket after receiving Nasdaq notice for non-compliance with equity requirement. - AInvest
Soligenix's 78.42% Surge on FDA Orphan Drug Designation Drives $890M Trading Volume Ranks 87th in Market Activity - AInvest
Penny Stocks on the Move: Today’s Top Gainers and Biggest Decliners - AInvest
FDA Grants Orphan Drug Designation to Soligenix's Dusquetide for Behçet’s Disease Treatment - citybuzz -
Soligenix Skyrockets 87%—Is This the Start of a Biotech Revolution? - AInvest
Top Midday Gainers - MarketScreener
Why Is Soligenix Stock Soaring On Monday? - Benzinga
Soligenix (SNGX.O) Makes Wild Intraday Move—What’s Driving It? - AInvest
Soligenix Shares Surge After FDA Grants Orphan Drug Status - MSN
Regression Model Predicts Rangebound Movement in Soligenix Inc.2025 Big Picture & Daily Technical Forecast Reports - beatles.ru
Soligenix stock soars after FDA grants orphan drug designation By Investing.com - Investing.com Canada
Soligenix (SNGX) up more than 300% since Jul 29 - AInvest
Soligenix stock soars after FDA grants orphan drug designation - Investing.com
FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results - The Malaysian Reserve
Soligenix (SNGX) Stock Surges on FDA Orphan Drug Designation for Rare Disease Treatment – A Big Win for This Biotech Underdog - RagingBull
Soligenix Inc.: An Unexpected Surge? - StocksToTrade
Soligenix Soars 90% on FDA Orphan Drug Designation – What’s Next for SNGX? - AInvest
Soligenix Gains FDA Orphan Drug Designation for Dusquetide - TipRanks
FDA grants soligenix orphan drug designation for behçet’s disease - Investing.com
Why Soligenix Is Rising In Pre-market? - Nasdaq
2025-08-18 | FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results | NDAQ:SNGX | Press Release - Stockhouse
Drawdown in Soligenix Inc. May Be Nearing EndStock Surge & AI Forecasted Entry and Exit Points - beatles.ru
Soligenix Faces Nasdaq Non-Compliance Notice - MSN
New Study Challenges Traditional Psoriasis Severity Classification - citybuzz -
Soligenix's Nasdaq Non-Compliance: A High-Stakes Balancing Act for Long-Term Investors - AInvest
Soligenix Receives Nasdaq Notice for Non-Compliance with Equity Requirement - AInvest
Soligenix Advances Heat-Stable Ricin Vaccine Amid Global Biothreat Concerns - citybuzz -
Soligenix receives Nasdaq notice for non-compliance with equity listing rule - Investing.com
Soligenix shares fall 5.78% premarket after announcing recent accomplishments and financial results. - AInvest
What makes Soligenix Inc. stock price move sharplyEarnings Beat & Smart Investment Allocation Insights - 선데이타임즈
Soligenix's Surprising Earnings Beat Amid Deepening Losses and High Volatility: A Biotech Inflection Point? - AInvest
Soligenix Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Soligenix Reports Q2 2025 Results, Confident in Late-Stage Rare Disease Pipeline - AInvest
Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results - Barchart.com
Soligenix’s Phase 3 Study on HyBryte for CTCL: Key Insights for Investors - MSN
Soligenix Inc. Stock Recovery Path — Analyst BreakdownJuly 2025 Rallies & Consistent Income Trade Recommendations - 선데이타임즈
Is Soligenix Inc. a stock for growth or value investorsFast Explosive Return Stocks - newsyoung.net
Alliance Global Partners Raises Soligenix Price Target Amid Clinical Advancements - citybuzz -
Alliance Global Partners Maintains Buy Rating, Increases Price Target as Soligenix (NASDAQ: SNGX) Advances Proprietary Clinical Programs - Barchart.com
How do insiders feel about Soligenix Inc.Free Investment Newsletter - classian.co.kr
Unraveling Soligenix’s Sharp Drop: Was It a Sell-Off or a Buying Opportunity? - AInvest
Relief Rally in Soligenix Inc. Stock — Can It HoldFast Entry High Potential Stock Alerts Triggered - beatles.ru
NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer - GlobeNewswire
Soligenix (NASDAQ: SNGX) Featured in NNW Editorial on Rare Disease Innovation - The Globe and Mail
Soligenix (NASDAQ: SNGX) Featured In NNW Editorial On Rare Disease Innovation - Barchart.com
Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy - GlobeNewswire
Breakthrough CTCL Cancer Treatment: Soligenix Advances US-Made HyBryte Platform as Aging Population Surges - Stock Titan
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators - The Malaysian Reserve
1.55%
0.38%
자본화:
|
볼륨(24시간):